Literature DB >> 24460263

RPSA gene mutants associated with risk of colorectal cancer among the chinese population.

Shan-Chun Zhang1, Wen Jin, Hui Liu, Ming-Juan Jin, Ze-Xin Chen, Zhe-Yuan Ding, Shuang-Shuang Zheng, Li-Juan Wang, Yun-Xian Yu, Kun Chen.   

Abstract

The primary aim of this study was to evaluate the relationship of single nucleotide polymorphisms (SNPs) in ribosomal protein SA (RPSA) gene with colorectal cancer (CRC). A case-control study including 388 controls and 387 patients with CRC was conducted in a Chinese population. Information about socio-demography and living behavior factors was collected by a structured questionnaire. Three SNPs (rs2133579, rs2269349, rs7641291) in RPSA gene were genotyped by Illumina SnapShot method. Multiple logistic regression models were used for assessing the joint effects between tea consumption and SNPs on CRC. The subjects with rs2269349 CC genotype had a decreased risk for CRC (OR=0.60; 95%CI = 0.37-0.99), compared with TT/CT genotype after adjustment for covariates. A similar association of rs2269349 with rectal cancer was observed (OR=0.49; 95%CI=0.24-1.00). Further analyses indicated that this SNP could modify the protective effect of tea drinking on CRC. Among the subjects with rs2269349 TT/CT or rs2133579 AA/GA, there was a marginal significantly lower risk of CRC (OR and 95%CI: 0.63 and 0.39-1.01 for rs2269349; 0.64 and 0.40-1.02 for rs2133579) in tea-drinking subjects in comparison to non-tea-drinking subjects. Mutants in the RPSA gene might be associated with genetic susceptibility to CRC and influence the protective effect of tea consumption in the Chinese population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24460263     DOI: 10.7314/apjcp.2013.14.12.7127

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  Pathways to Specialized Ribosomes: The Brussels Lecture.

Authors:  Jonathan D Dinman
Journal:  J Mol Biol       Date:  2016-01-04       Impact factor: 5.469

2.  CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.

Authors:  L H Zhao; Q L Lin; J Wei; Y L Huai; K J Wang; H Y Yan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn.

Authors:  Xiupeng Zhang; Yuan Miao; Xinmiao Yu; Yong Zhang; Guiyang Jiang; Yang Liu; Juanhan Yu; Qiang Han; Huanyu Zhao; Enhua Wang
Journal:  Tumour Biol       Date:  2015-03-04

4.  A novel biomarker C6orf106 promotes the malignant progression of breast cancer.

Authors:  Guiyang Jiang; Xiupeng Zhang; Yong Zhang; Liang Wang; Chuifeng Fan; Hongtao Xu; Yuan Miao; Enhua Wang
Journal:  Tumour Biol       Date:  2015-05-08

5.  High SHIP2 expression indicates poor survival in colorectal cancer.

Authors:  Ju Yang; Maoying Fu; Yaoguang Ding; Yajing Weng; Weifei Fan; Xiaolin Pu; Zhijun Ge; Feng Zhan; Huihui Ni; Wei Zhang; Feng Jin; Ning Xu; Jiang Li; Liang Qiu; Jun Wang; Xuefeng Gu
Journal:  Dis Markers       Date:  2014-11-24       Impact factor: 3.434

6.  QuaDMutEx: quadratic driver mutation explorer.

Authors:  Yahya Bokhari; Tomasz Arodz
Journal:  BMC Bioinformatics       Date:  2017-10-24       Impact factor: 3.169

7.  Green tea (Camellia sinensis) for the prevention of cancer.

Authors:  Tommaso Filippini; Marcella Malavolti; Francesca Borrelli; Angelo A Izzo; Susan J Fairweather-Tait; Markus Horneber; Marco Vinceti
Journal:  Cochrane Database Syst Rev       Date:  2020-03-02

8.  Identifying and analyzing different cancer subtypes using RNA-seq data of blood platelets.

Authors:  Yu-Hang Zhang; Tao Huang; Lei Chen; YaoChen Xu; Yu Hu; Lan-Dian Hu; Yudong Cai; Xiangyin Kong
Journal:  Oncotarget       Date:  2017-09-15

9.  Identification of key regulators in prostate cancer from gene expression datasets of patients.

Authors:  Irengbam Rocky Mangangcha; Md Zubbair Malik; Ömer Küçük; Shakir Ali; R K Brojen Singh
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.